{
    "relation": [
        [
            "",
            "Benazepril / Amlodipine",
            "Benazepril / HCTZ"
        ],
        [
            "Description",
            "Benazepril hydrochloride (HCl)/amlodipine besylate: 20/5 mg (Dose Level 1), 40/5 mg (Dose Level 2), and 40/10 mg (Dose Level 3) capsules for oral administration once daily",
            "Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ): 20/12.5 mg (Dose Level 1), 40/12.5 mg (Dose Level 2), and 40/25 mg (Dose Level 3) capsules for oral administration once daily"
        ]
    ],
    "pageTitle": "Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00170950?sect=X30125&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990611.52/warc/CC-MAIN-20150728002310-00133-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 856626843,
    "recordOffset": 856597726,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1 Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1 Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2 Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Benazepril/Amlodipine \u00a0 \u00a0 Benazepril/Hydrochlorothiazide \u00a0 STARTED \u00a0 \u00a0 5744 \u00a0 \u00a0 5762 \u00a0 COMPLETED \u00a0 \u00a0 4859 \u00a0 \u00a0 4852 \u00a0 NOT COMPLETED \u00a0 \u00a0 885 \u00a0 \u00a0 910 \u00a0 Death \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 236 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 274 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 496 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 498 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 134 \u00a0 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}